Skip to main navigation Skip to search Skip to main content

Targeting driver mutations in lung cancer with interstitial pneumonia: A nationwide study in Japan

  • Satoshi Ikeda
  • , Takashi Ogura
  • , Toshihiro Misumi
  • , Yasuhiko Nishioka
  • , Seishu Hashimoto
  • , Kazuya Ichikado
  • , Aya Fukuizumi
  • , Saori Takata
  • , Taku Itoh
  • , Yuki Sato
  • , Kyoichi Okishio
  • , Kazuhiro Yatera
  • , Noriho Sakamoto
  • , Motoyasu Kato
  • , Ryota Kikuchi
  • , Takayuki Honda
  • , Naozumi Hashimoto
  • , Koji Murakami
  • , Takuma Isshiki
  • , Mayuka Yamane
  • Masato Karayama, Atsushi Miyamoto, Yuriko Ishida, Minehiko Inomata, Hirotaka Nishikiori, Kakuhiro Yamaguchi, Hisanori Amimoto, Kentaro Tamura, Toyoshi Yanagihara, Yoshinori Tanino, Junji Koyama, Nozomu Tsurumaki, Yuko Waseda, Tomoo Kishaba, Hiroaki Ozasa, Masaru Matsumoto, Yoshiaki Kinoshita, Yutaro Nakamura, Hiroyoshi Yamauchi, Kazuma Kishi

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction Non-small cell lung cancer (NSCLC) patients with comorbid interstitial pneumonia (IP) are at high risk for drug-induced pneumonitis, and previous reports suggest a lower frequency of common driver mutations such as EGFR . This may discourage genetic testing, potentially overlooking prevalent, targetable mutations like KRAS , BRAF , and MET . This study aimed to elucidate the real-world status of genetic testing, the frequency of oncogenic drivers, and the safety and efficacy of targeted therapies in patients with NSCLC and comorbid IP. Methods This multicenter, retrospective study analyzed 1256 patients with advanced or recurrent NSCLC and comorbid chronic fibrosing IP from 37 Japanese institutions (Registry number: UMIN000055609). Results The rate of any genetic testing was 59.2 % (95 % confidence interval [CI], 56.5–62.0), with multigene testing performed in only 41.0 % (95 %CI, 38.3–43.8). Among patients with NSCLC undergoing multigene testing (N = 515), the most frequent mutations were KRAS (4.7 %; G12C, 1.9 %), followed by EGFR (2.9 %), BRAF V600E (1.6 %), and MET exon 14 skipping (1.6 %). The incidence of drug-induced pneumonitis was 0 % (0/6) for sotorasib, 50 % (4/8) for osimertinib, 33 % (1/3) for alectinib, and 25 % (1/4) for both dabrafenib plus trametinib and tepotinib. Patients with actionable oncogenic drivers receiving targeted therapy had the longest overall survival, followed by those not receiving it, and then driver-negative/unknown patients (median: 39.2, 24.0, and 13.8 months, respectively). Conclusions Multigene testing is underutilized in this population. While many targeted therapies carry a high risk of pneumonitis, sotorasib appeared relatively safe. Despite the risks, identifying and treating actionable oncogenic drivers may improve survival.

Original languageEnglish
Article number116232
JournalEuropean Journal of Cancer
Volume235
DOIs
Publication statusPublished - 25-02-2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Targeting driver mutations in lung cancer with interstitial pneumonia: A nationwide study in Japan'. Together they form a unique fingerprint.

Cite this